P. Jeffrey Conn

Metabotropic glutamate receptors as therapeutic targets for schizophrenia

P. Conn, P. Vinson, P. Jeffrey Conn, 2012, Neuropharmacology.

Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells

D. Sheffler, P. Conn, P. Jeffrey Conn, 2008, Neuropharmacology.

Development of allosteric modulators of GPCRs for treatment of CNS disorders

P. Jeffrey Conn, P. Conn, Hilary Highfield Nickols, 2014, Neurobiology of Disease.

Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice

P. Conn, Y. Nong, T. de Paulis, 2006, Journal of Pharmacology and Experimental Therapeutics.

Peripheral glutamate receptors: molecular biology and role in taste sensation.

R. Dingledine, P. Conn, P. Jeffrey Conn, 2000, The Journal of nutrition.

Clozapine Potentiation of N-Methyl-d-aspartate Receptor Currents in the Nucleus Accumbens: Role of NR2B and Protein Kinase A/Src Kinases

D. Henze, P. Conn, G. Seabrook, 2005, Journal of Pharmacology and Experimental Therapeutics.

The Glycine Transporter Type 1 Inhibitor N-[3-(4′-Fluorophenyl)-3-(4′-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior

P. Mallorga, P. Conn, Wei Lemaire, 2003, The Journal of Neuroscience.

Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats.

D. Sheffler, N. Cosford, P. Conn, 2011, Journal of medicinal chemistry.